Valvular Regurgitation is a common valvular heart disease (VHD) where the failure of the heart’s valve to close tightly allows blood to flow backward.  Patients can have shortness of breath, fatigue, chest pain, fluttering heartbeat, and sometimes death.

About 15% of people 75 years and over have valvular heart disease and affects at least 2.5% of the U.S. population. The worldwide Valvular Heart Disease burden is estimated at hundreds of millions.¹⁻²

The Mitral and Tricuspid Valve Regurgitation market size alone is forecast to reach an estimated $5.0 Billion by 2028.  

Growing incidence of cases of coronary artery diseases, the growing geriatric population, changes in the lifestyle of people, and the growth of minimally invasive treatment methods are all factors that are likely to drive the valvular heart disease treatment market during the forecast period 2021-2025.

Currently, ConKay Medical Systems is first focusing on treating the Tricuspid valve.